Status:

COMPLETED

Effects of Device-assisted Practice of ADL on Arm/Hand Recovery in Individuals With Moderate to Severe Stroke

Lead Sponsor:

Northwestern University

Collaborating Sponsors:

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Conditions:

Stroke

Eligibility:

All Genders

21-80 years

Phase:

NA

Brief Summary

A large number of post-stroke survivors cannot functionally use their paretic upper extremity (UE). This study therefore investigates effects of device-assisted practice of activities of daily living ...

Detailed Description

Thirty subjects for each group will be recruited. A REDCap database for this study will be setup to manage every step involved in the protocol. All the potential subjects will go through standardized ...

Eligibility Criteria

Inclusion

  • Age between 21-80
  • Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (UE FMA in the range of 10-40/66, CMSA\_H stage of the hand section \<=4)
  • Capacity to provide informed consent
  • Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate some active elbow extension
  • Ability to open hand with a thumb-to-index finger distance ≥4 cm, with the assistance of the ReIn-Hand device with the help of a physical therapist
  • MRI compatible
  • Discharged from all forms of physical rehabilitation
  • Intact skin on the hemiparetic arm
  • Be tolerate sitting for no less than 1 hour
  • Montreal Cognitive Assessment (MoCA) score \>=23

Exclusion

  • Motor or sensory impairment in the non-affected limb
  • Any brainstem and/or cerebellar lesion
  • Severe concurrent medical problems (e.g. cardiorespiratory impairment, uncontrolled hypertension, inflammatory joint disease)
  • History of neurologic disorder other than stroke (Parkinson's Disease, Acute Lateral Sclerosis, Multiple Sclerosis, Traumatic Brain Injury, peripheral neuropathy, Amyotrophic lateral sclerosis, spinal cord injury, Dementia)
  • Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale
  • Using cardiac pacemaker, implanted cardioverter defibrillator, neurostimulation system inside the brain or spinal cord, bone growth box fusion stimulation
  • Seizure in the last 6 months
  • Severe upper extremity sensory impairment indicated by absent sensation on the tactile sensation subscale (light touch and pressure items) of the Revised Nottingham Assessment of Somato-Sensations (score\<4)
  • Chemo denervation: botulinum toxin, dysport, or Myobloc or phenol block injection to any portion of the paretic UE within the last 6 months, or phenol/alcohol injections \<12 months before participation
  • Unable to passively attain 90 degrees of shoulder flexion and abduction, measured using a goniometer based on adapted methods
  • Flexion contractures larger than 45 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) of thumb and index finger
  • Pregnant or planning to become pregnant
  • Participating in any experimental rehabilitation or drug studies
  • Inability to attend intervention sessions 3 times a week during 8 weeks, as well as to assessments/evaluations and follow up
  • Upper extremity musculoskeletal impairment limiting function prior to stroke
  • Currently using oxygen
  • Upper limb amputation

Key Trial Info

Start Date :

September 23 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 16 2024

Estimated Enrollment :

54 Patients enrolled

Trial Details

Trial ID

NCT04077073

Start Date

September 23 2019

End Date

December 16 2024

Last Update

February 17 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

645 N Michigan Ave, Suite 1100

Chicago, Illinois, United States, 60611

2

Northwestern University, Dept. of PTHMS

Chicago, Illinois, United States, 60611